UPDATE Thursday, April 22, 2021, 1:00 p.m. EDT—U.S. House Energy and Commerce (E&C) Chair Frank Pallone this morning introduced a significantly slimmed-down version of H.R. 3, the drug pricing bill that the House passed during the last session of Congress but the then-GOP-controlled Senate let die.
The revised House bill does not include language from the original bill, strongly opposed by 340B covered entities, that entities say would foreclose all remaining profits on 340B-purchased drugs billed to state Medicaid agencies.
U.S. House Energy and Commerce (E&C) Chair Frank Pallone this morning introduced a significantly slimmed-down version of H.R. 3, the drug pricing bill that the House passed during the last session of Congress but the then-GOP-controlled Senate let die.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
